Abstract 3021
Background
Follicular lymphoma (FL) is an indolent non-Hodgkin’s lymphoma with heterogeneous outcomes among patients. Casulo et al (JCO 2015) showed that progression of disease within 2 years (POD24) after diagnosis for FL patients treated by R-CHOP was associated with poor outcomes, needing further validations before using it as a standard endpoint to evaluate treatment efficacy. We investigated the POD24 predictive value for all patients treated or not with R-CHOP in our institution (Nantes Medical University, France).
Methods
Patients with grade 1, 2 or 3a FL treated from 2007 were registered in our local database (approved by French authorities, CNIL) and included in the present retrospective monocentric study, with up-dating of patient’s outcomes. FL diagnosis was performed by local pathologist experts (members of the national LYSA-pathologist group, France).
Results
Between 2007 and 2016, 317 patients with confirmed FL were included. At diagnosis: 24 did not received any treatment (Wait and watch), 259 were treated with Rituximab (R) (including R alone in 98 cases), 143 received an anthracycline-containing regimen (mainly R-CHOP like), 5 received bendamustine-containing regimen, radiotherapy alone in 11 cases and another chemotherapy regimen in 36 cases (mainly R-COP). Second line treatment (N = 151) consisted of chemotherapy in 91 cases, R alone in 37 cases. After first line therapy, 61 patients relapsed or died within 2y (POD24+), 99 patients after 2y, including 21 transformations, and 154 patients did not progress or die (missing = 3). At the time of the present analysis, the median follow-up is 5y. Median PFS is 58.2 months. OS at 1y, 3y, and 5y are 98.4% [97.0-99.8], 95.1% [92.6-97.6] and 92.5% [89.3-95.9] respectively. The 5y OS was statistically worst for POD24+ patients (82 % [71.9-93.5]) than for POD24- patients (93.3% [88.98-97.8]) (p = 0.00001). Age at diagnosis (≥60), performance status (PS ≥ 1), FLIPI, FLIPI2 scores (high) and transformation are predictive of OS in univariate analysis. PS (≥1) at diagnostic is predictive of POD24+.
Conclusions
POD24 is predictive of a worse OS regardless of first line treatment nature and can be recommended as a relevant endpoint for clinical trials.
Clinical trial identification
Legal entity responsible for the study
CHU de Nantes.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract